980 3383-0

IPOS's Copy.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/19, 31/215, 31/34, 31/44

A2

(11) International Publication Number: WO 97/24116

(43) International Publication Date: 10 July 1997 (10.07.97)

(21) International Application Number: PCT/US96/20511

(22) International Filing Date: 16 December 1996 (16.12.96)

(30) Priority Data: 08/580,553 29 December 1995 (29.12.95) US

(71) Applicant: ALLERGAN [US/US]; 8301 Mars Drive, Waco, TX 76712 (US). pls see letter of 10/8/99

(72) Inventors: TENG, Min; 2 Dove Street, Aliso Viejo, CA 92656 (US). DUONG, Tien, T.; Apartment 15C, 13 Bearpaw, Irvine, CA 92714 (US). CHANDRARATNA, Roshantha, A.; 25841 Empresa, Mission Viejo, CA 92691 (US).

(74) Agents: BARAN, Robert, J. et al.; Allergan, Inc., 2525 Dupont Drive, T-2,2-E, P.O. Box 19534, Irvine, CA 92623-9534 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY

(57) Abstract

Retinoid compounds which act specifically or selectively on RARα receptor subtypes in preference over RARβ and RARγ receptor subtypes, possess desirable pharmaceutical properties associated with retinoids, and are particularly suitable for treatment of tumors, such as acute monocytic leukemia, cervical carcinoma, myeloma, ovarian carcinomas and head and neck carcinomas, without having one or more undesirable side effects of retinoids, such as inducement of weight loss, mucocutaneous toxicity, skin irritation and teratogenicity.